Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPRAZOLAM vs STELAZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
Schizophrenia,Short-term treatment of generalized non-psychotic anxiety (off-label)
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Hepatic via CYP450 enzymes (primarily CYP2D6); also undergoes N-demethylation and sulfoxidation.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
80% (primarily to albumin, minor to α1-acid glycoprotein)
92-97% bound to albumin and alpha-1 acid glycoprotein.
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
Approximately 18-30 L/kg (0.5-1.5 L/kg). Clinical meaning: Extensive tissue distribution with high CNS penetration.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
Oral: ~40% (due to first-pass metabolism); IM: 100%.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
No specific dose adjustment recommended; use caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use or reduce dose by 75%.
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
Children 6-12 years: 1 mg 1-2 times daily; increase gradually up to 15 mg/day. Children >12 years: adult dosing.
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
Initiate at 1-2 mg twice daily; titrate slowly due to increased sensitivity and risk of orthostatic hypotension and extrapyramidal symptoms.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Increased mortality in elderly patients with dementia-related psychosis.
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation, leukopenia/neutropenia/agranulocytosis, seizure threshold lowering, anticholinergic effects, hypotension, cholestatic jaundice, ocular changes (corneal/lenticular deposits).
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
Comatose states, CNS depression (e.g., barbiturates, alcohol), bone marrow depression, blood dyscrasias, hepatic disease, hypersensitivity to phenothiazines.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
Avoid alcohol and CNS depressants. Grapefruit juice may increase drug levels; avoid concurrent use. Limit caffeine intake. No specific dietary restrictions, but monitor weight gain due to increased appetite.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimesters: Risk of extrapyramidal symptoms, jaundice, and hyperreflexia in neonates with late exposure. Case reports of neonatal withdrawal and EPS. Not a known major teratogen but use only if benefits outweigh risks.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
Excreted in breast milk in small amounts; relative infant dose est. ~0.1-0.5% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, EPS, and poor feeding. Generally considered compatible with breastfeeding with caution.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
Increased clearance in pregnancy may necessitate dose titration. Start at low end of dosing range; increase gradually based on response and tolerability. Monitor for relapse. Postpartum dose may need reduction due to restored clearance. No specific PK studies available; clinical judgment advised.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
Extrapyramidal symptoms (EPS) are common; use benztropine prophylactically in young males. Monitor for QT prolongation, especially in elderly. Avoid in patients with history of tardive dyskinesia. Can cause orthostatic hypotension; titrate slowly. Neuroleptic malignant syndrome (NMS) rare but serious; discontinue immediately if hyperthermia, rigidity, autonomic instability occur.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness upon standing; rise slowly from sitting or lying down.,Report any involuntary muscle movements, stiffness, or tremors to your doctor.,Avoid alcohol and other central nervous system depressants.,May cause drowsiness; use caution when driving or operating machinery.,Notify your doctor if you experience rapid heartbeat, fainting, or fever with muscle rigidity.,Avoid exposure to extreme heat (can impair body temperature regulation).,Store at room temperature away from light and moisture.
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPRAZOLAM vs STELAZINE, answered by our medical review team.
ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. STELAZINE is a Phenothiazine Antipsychotic that works by Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPRAZOLAM and STELAZINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. The standard adult dose of STELAZINE is: Adults: 2-10 mg orally twice daily; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPRAZOLAM and STELAZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. STELAZINE is classified as Category C. First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimester. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.